Drug Profile
PB 105
Alternative Names: LEC/rituximab; PB105; Rituximab biobetter - Pivotal BiosciencesLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Pivotal BioSciences
- Class Antineoplastics; Biobetters; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 23 Sep 2015 Preclinical trials in Cancer in USA (Parenteral) before September 2015